Tomoyuki Nishida
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial.
Journal: Journal of gastroenterology
Published: June 16, 2026
Correction: Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.
Journal: Diabetologia
Published: May 05, 2025
Effect of once-weekly subcutaneous semaglutide on abdominal visceral fat area in Japanese adults with overweight and obesity: A post hoc analysis of the STEP 6 trial.
Journal: Obesity research & clinical practice
Published: November 22, 2024
Pharmacological characteristics of once-weekly insulin icodec in Japanese individuals with type 1 diabetes.
Journal: Journal of diabetes investigation
Published: October 07, 2024
Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis.
Journal: Obesity research & clinical practice
Published: July 08, 2024
Efficacy and safety of once-weekly insulin icodec versus once-daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials.
Journal: Diabetes, obesity & metabolism
Published: May 29, 2024
Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1.
Journal: The lancet. Diabetes & endocrinology
Published: February 07, 2024
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
Journal: The New England journal of medicine
Published: June 25, 2023
Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post-hoc analysis.
Journal: Journal of diabetes investigation
Published: June 24, 2022
Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index.
Journal: Journal of diabetes investigation
Published: November 19, 2021
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
Journal: The lancet. Diabetes & endocrinology
Published: November 03, 2021
Last Updated: 09/26/2026